Frida Rantanen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frida Rantanen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Ungureanu
Disease Networks Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
3 shared publications Astrid Murumägi
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
2 shared publicationsElina Multamäki
Disease Networks Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
2 shared publicationsAdolfo J. Sáen Marín
Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcala, Spain
1 shared publicationAino-Maija Kiiski
Disease Networks Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
1 shared publicationAlberto Alvarez-Larrán
Department of Hematology, Hospital del Mar, Barcelona, Spain; Department of Hematology, Clinic Hospital, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 29 June 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (8) , 101617
Platelet proteome links metabolism to reactivity in Essential Thrombocythemia
- 29 June 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (8) , 101617
Open AccessPlatelet proteome links metabolism to reactivity in Essential Thrombocythemia
- Open Access
- 27 February 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer
Drug resistance remains a major challenge to durable responses in ovarian cancer, the fifth leading cause of cancer-related death among women. In this study, we developed long-term resistant (lt-res, several months) pre-clinical models of two drugs inducing mitotic arrest in TP53 -mutated cells: adavosertib (ADA), an investigational WEE1 inhibitor targeting the DNA damage response and currently evaluated in clinical trials, and paclitaxel (PTX), a widely used chemotherapeutic agent in cancer care targeting microtubules. Through integrated multi-omics functional profiling, we identify a shared PI3K/AKT-regulated signaling node that governs drug adaptation across all lt-res models. This node modulates the activity of DNA-damage responses and genotoxic stress to toggle between two adaptive states: activated PI3K/AKT driving a proliferative “fast-bypass” program with sustained cell cycle progression and mitotic evasion, or reduced PI3K/AKT signaling initiating a “slow-repair” state characterized by DNA damage checkpoint engagement, replication slowdown, and increased drug efflux. Notably, upregulation of receptor tyrosine kinases, such as ROR1, was observed in both ADA and PTX lt-res models with activated PI3K/AKT signaling. Targeting ROR1 with zilovertamab-vedotin, a monoclonal antibody-drug conjugate, resulted in enhanced cytotoxicity, demonstrating a new approach against recurrent drug-resistant ovarian cancer.
- 27 February 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer
Drug resistance remains a major challenge to durable responses in ovarian cancer, the fifth leading cause of cancer-related death among women. In this study, we developed long-term resistant (lt-res, several months) pre-clinical models of two drugs inducing mitotic arrest in TP53 -mutated cells: adavosertib (ADA), an investigational WEE1 inhibitor targeting the DNA damage response and currently evaluated in clinical trials, and paclitaxel (PTX), a widely used chemotherapeutic agent in cancer care targeting microtubules. Through integrated multi-omics functional profiling, we identify a shared PI3K/AKT-regulated signaling node that governs drug adaptation across all lt-res models. This node modulates the activity of DNA-damage responses and genotoxic stress to toggle between two adaptive states: activated PI3K/AKT driving a proliferative “fast-bypass” program with sustained cell cycle progression and mitotic evasion, or reduced PI3K/AKT signaling initiating a “slow-repair” state characterized by DNA damage checkpoint engagement, replication slowdown, and increased drug efflux. Notably, upregulation of receptor tyrosine kinases, such as ROR1, was observed in both ADA and PTX lt-res models with activated PI3K/AKT signaling. Targeting ROR1 with zilovertamab-vedotin, a monoclonal antibody-drug conjugate, resulted in enhanced cytotoxicity, demonstrating a new approach against recurrent drug-resistant ovarian cancer.
- Open Access
- 1 January 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (1) , 4
Precision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond
Editorial Commentary Precision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond Frida Rantanen, Daniela Ungureanu
- 1 January 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (1) , 4
Open AccessPrecision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond
Editorial Commentary Precision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond Frida Rantanen, Daniela Ungureanu
- Open Access
- 6 November 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-10
Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities
Cancer-associated fibroblasts (CAFs) are central architects of the prostate cancer (PCa) microenvironment, yet their phenotypic diversity and druggable vulnerabilities remain largely uncharted. Here, we present an integrative multi-omics characterization of primary ex vivo CAFs from seven treatment-naïve PCa patients. Using single-cell RNA sequencing (scRNA-seq), we uncover substantial transcriptional heterogeneity among CAFs, with distinct gene expression programs related to extracellular matrix remodeling, inflammation, immune modulation, and metabolic reprogramming. This phenotypic diversity was further supported by variable expression of canonical stromal markers, including FAP, SULF1, VIM, CAV1, and αSMA. Transcription factor network analysis revealed SOX, FOX, and STAT3 family members as key regulators of pro-tumorigenic CAF states. To probe therapeutic vulnerabilities, we performed high-throughput drug sensitivity and resistance testing (DSRT) across 396 oncology compounds. CAFs exhibited broad sensitivity to multikinase inhibitors, with dasatinib, midostaurin, and FGFR inhibitors (AZD4547, erdafitinib) emerging as top stromal-directed candidates. These findings underscore the plasticity of prostate CAFs and reveal actionable vulnerabilities, supporting the development of targeted stromal therapies to disrupt tumor-stroma interactions in PCa.
- 6 November 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-10
Open AccessMolecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities
Cancer-associated fibroblasts (CAFs) are central architects of the prostate cancer (PCa) microenvironment, yet their phenotypic diversity and druggable vulnerabilities remain largely uncharted. Here, we present an integrative multi-omics characterization of primary ex vivo CAFs from seven treatment-naïve PCa patients. Using single-cell RNA sequencing (scRNA-seq), we uncover substantial transcriptional heterogeneity among CAFs, with distinct gene expression programs related to extracellular matrix remodeling, inflammation, immune modulation, and metabolic reprogramming. This phenotypic diversity was further supported by variable expression of canonical stromal markers, including FAP, SULF1, VIM, CAV1, and αSMA. Transcription factor network analysis revealed SOX, FOX, and STAT3 family members as key regulators of pro-tumorigenic CAF states. To probe therapeutic vulnerabilities, we performed high-throughput drug sensitivity and resistance testing (DSRT) across 396 oncology compounds. CAFs exhibited broad sensitivity to multikinase inhibitors, with dasatinib, midostaurin, and FGFR inhibitors (AZD4547, erdafitinib) emerging as top stromal-directed candidates. These findings underscore the plasticity of prostate CAFs and reveal actionable vulnerabilities, supporting the development of targeted stromal therapies to disrupt tumor-stroma interactions in PCa.